<div id="readability-page-1">Shares of Doximity, Inc. (NYSE:DOCS - Get Free Report) have received an average rating of &#34;Buy&#34; from the five brokerages that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company.<ul><li>The Best Stocks Under $100 to Buy Now</li></ul>A number of brokerages recently weighed in on DOCS. Wall Street Zen lowered Doximity from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. Weiss Ratings restated a &#34;hold (c+)&#34; rating on shares of Doximity in a research report on Wednesday, December 24th. Royal Bank Of Canada raised shares of Doximity to a &#34;moderate buy&#34; rating in a research note on Thursday. Barclays raised shares of Doximity to a &#34;strong-buy&#34; rating in a research note on Monday, December 8th. Finally, Truist Financial upgraded shares of Doximity from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Thursday.Read Our Latest Report on DOCS<h2>Doximity News Roundup</h2><ul><li>2 New IPOs with Explosive Potential</li></ul>Here are the key news stories impacting Doximity this week:<ul> <li>Positive Sentiment: Truist upgraded DOCS from &#34;hold&#34; to &#34;strong-buy,&#34; signaling conviction in near-term upside and product/market momentum that could support a rebound in shares. Truist Upgrade</li> <li>Positive Sentiment: Royal Bank of Canada (RBC) moved DOCS to a &#34;moderate buy,&#34; citing a durable growth moat—this bolsters the long-term growth thesis and may attract buyers looking past recent volatility. RBC Coverage</li> <li>Positive Sentiment: Goldman Sachs upgraded DOCS from &#34;strong sell&#34; to &#34;hold&#34; — a move that reduces downside risk from a major house, even as Goldman warns of a valuation reset; the change can remove selling pressure tied to the prior very negative rating. Goldman Upgrade</li> <li>Neutral Sentiment: Coverage pieces assess DOCS vs. peers and provide a critical review of positioning—useful context for investors but not an immediate catalyst by themselves. Competitor Review</li> <li>Neutral Sentiment: Yahoo Finance examines valuation after volatile trading and discusses recent AI product updates; product developments are positive, but valuation and volatility keep the near-term outlook mixed. Valuation &amp; AI Update</li> <li>Negative Sentiment: Wall Street Zen lowered DOCS to a &#34;hold,&#34; which could add selling pressure among investors who react to fresh downgrades and heighten short-term caution. Wall Street Zen Downgrade</li> </ul><h2>Doximity Stock Performance</h2>NYSE DOCS opened at $43.85 on Friday. The company has a market cap of $8.26 billion, a P/E ratio of 34.80, a price-to-earnings-growth ratio of 2.03 and a beta of 1.39. Doximity has a one year low of $43.21 and a one year high of $85.21. <h2>About Doximity</h2> (Get Free Report)Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers. The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.<h2>Recommended Stories</h2><ul><li>Five stocks we like better than Doximity</li><li>Why Trump and Musk suddenly care about Fort Knox</li><li>Do not delete, read immediately</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>Buy this stock tomorrow?</li><li>Claim Your Share of $5.39 BILLION in AI Equity Checks</li></ul><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURPQ1M?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURPQ1M"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Doximity Right Now?</h2>Before you consider Doximity, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.While Doximity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

DOCS

Doximity, Inc. (NYSE:DOCS) has received an average rating of "Buy" from five brokerages, with two hold ratings, one buy, and two strong buy ratings. Recent analyst actions include upgrades from Truist Financial and Royal Bank of Canada, while Wall Street Zen downgraded the stock to hold. Doximity operates a digital network for healthcare professionals, facilitating communication and telehealth services. The stock opened at $43.85, with a market cap of $8.26 billion and a P/E ratio of 34.80.

Doximity, Inc. (NYSE:DOCS) Given Consensus Rating of "Buy" by Analysts